You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Claims for Patent: 5,972,916


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,972,916
Title: Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
Abstract:The invention provides a safe and economical nonprescription combination of acetaminophen, aspirin and caffeine (APAP/ASA/CAF) for use in treating migraine pain and the cluster of symptoms characteristic of migraine attack, such as nausea, photophobia, phonophobia and functional disabilities. The use of the APAP/ASA/CAF combination is also effective in aborting the prodrome phase of a migraine attack.
Inventor(s): Armellino; Joseph (Chester, NJ), Koslo; Randy (West Windsor Township, NJ)
Assignee: Bristol-Myers Squibb Company (New York, NY)
Application Number:09/021,284
Patent Claims: 1. A method for treating migraine pain and the cluster of symptoms characteristic of a migraine attack, the symptoms selected from the group consisting of nausea, photophobia, phonophobia and functional disability, comprising administering to a human subject a composition comprising a combination of acetaminophen, aspirin and caffeine in an amount effective to reduce or eliminate the migraine pain and one or more of said symptoms characteristic of migraine.

2. The method according to claim 1, wherein two or more of said symptoms characteristic of migraine are reduced or eliminated.

3. The method according to claim 1, wherein said composition is administered in a solid oral dosage form.

4. The method according to claim 3, wherein said dosage form is selected from the group consisting of tablets, pills, caplets and capsules.

5. The method according to claim 1, wherein said composition is administered as a suppository.

6. The method according to claim 4, wherein a single tablet, pill or capsule of said solid dosage form comprises acetaminophen in an amount of from about 200 to about 300 mg; aspirin in an amount of from about 200 to about 300 mg; and caffeine in an amount of about 55 to about 100 mg.

7. The method according to claim 5, wherein said composition comprises acetaminophen in an amount of 250 mg; aspirin in an amount of 250 mg; and caffeine in an amount of 65 mg.

8. The method according to claim 5, wherein two tablets, pills or capsules are administered to the human host about every four to six hours.

9. The method according to claim 7, wherein said composition is not readministered to said subject more frequently than once every six hours.

10. The method according to claim 1, wherein the amount of composition administered is effective to reduce or eliminate the migraine pain and two or more of said symptoms characteristic of migraine.

11. The method according to claim 1, wherein the amount of composition administered is effective to reduce or eliminate the migraine pain and three or more of said symptoms characteristic of migraine.

12. The method according to claim 1, wherein the amount of composition administered is effective to reduce or eliminate the migraine pain and all four of said symptoms characteristic of migraine.

13. A method of aborting a migraine attack, wherein the migraine attack is characterized by any one of the symptoms selected from the group consisting of nausea, photophobia, phonophobia and functional disability, comprising administering to a human subject during the prodrome phase of the migraine attack a migraine abortive effective amount of a composition comprising a combination of acetaminophen, aspirin and caffeine.

14. A method for treating migraine pain and nausea characteristic of a migraine attack comprising administering to a human subject a composition comprising a combination of acetaminophen, aspirin, and caffeine in an amount effective to reduce or eliminate the migraine pain and nausea characteristic of a migraine attack.

15. A method for treating migraine pain and photophobia characteristic of a migraine attack comprising administering to a human subject a composition comprising a combination of acetaminophen, aspirin, and caffeine in an amount effective to reduce or eliminate the migraine pain and photophobia characteristic of a migraine attack.

16. A method for treating migraine pain and phonophobia characteristic of a migraine attack comprising administering to a human subject a composition comprising a combination of acetaminophen, aspirin, and caffeine in an amount effective to reduce or eliminate the migraine pain and phonophobia characteristic of a migraine attack.

17. A method for treating migraine pain and functional disability characteristic of a migraine attack comprising administering to a human subject a composition comprising a combination of acetaminophen, aspirin, and caffeine in an amount effective to reduce or eliminate the migraine pain and functional disability characteristic of a migraine attack.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.